Schrödinger (NASDAQ:SDGR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Insider & Institutional Ownership
41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Schrödinger and Olema Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Schrödinger | 0 | 1 | 3 | 0 | 2.75 |
Olema Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
Schrödinger currently has a consensus target price of $85.50, indicating a potential upside of 15.70%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 84.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Schrödinger.
Valuation & Earnings
This table compares Schrödinger and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Schrödinger | $85.54 million | 60.48 | $-24,570,000.00 | N/A | N/A |
Olema Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
Olema Pharmaceuticals has lower revenue, but higher earnings than Schrödinger.
Profitability
This table compares Schrödinger and Olema Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Schrödinger | -19.92% | -7.25% | -5.33% |
Olema Pharmaceuticals | N/A | N/A | N/A |
Summary
Olema Pharmaceuticals beats Schrödinger on 6 of the 8 factors compared between the two stocks.